Schneider Electric Expands Youth Partnership with Enactus to Drive Inclusive Energy Transition in Egypt    China's Jiangsu Zhengyong to build $85m factory in Egypt's Ain Sokhna: SCZONE    Egyptian pound ticks up vs. US dollar at Thursday's close    Egypt condemns Israeli plan to build 3,400 settler homes in West Bank    Fitch Ratings: ASEAN Islamic finance set to surpass $1t by 2026-end    Egypt, Namibia explore closer pharmaceutical cooperation    Egypt, China ink $1bn agreement for Sailun tire plant in SCZONE    Renowned Egyptian novelist Sonallah Ibrahim dies at 88    Egypt's Electricity Minister discusses progress on Greece power link    Egypt's FM discusses Gaza, bilateral ties in calls with Saudi, South African counterparts    Egypt prepares to tackle seasonal air pollution in Nile Delta    27 Western countries issue joint call for unimpeded aid access to Gaza    Egyptian, Ugandan Presidents open business forum to boost trade    Al-Sisi says any party thinking Egypt will neglect water rights is 'completely mistaken'    Egypt's Sisi warns against unilateral Nile measures, reaffirms Egypt's water security stance    Egypt's Sisi, Uganda's Museveni discuss boosting ties    Egypt, Colombia discuss medical support for Palestinians injured in Gaza    Australia to recognise Palestinian state in September, New Zealand to decide    Egypt, Huawei explore healthcare digital transformation cooperation    Global matcha market to surpass $7bn by 2030: Nutrition expert    Egypt's Sisi, Sudan's Idris discuss strategic ties, stability    Egypt's govt. issues licensing controls for used cooking oil activities    Egypt to inaugurate Grand Egyptian Museum on 1 November    Egypt, Uganda strengthen water cooperation, address Nile governance    Egypt's Sisi: Egypt is gateway for aid to Gaza, not displacement    Korean Cultural Centre in Cairo launches folk painting workshop    Greco-Roman rock-cut tombs unearthed in Egypt's Aswan    Egypt reveals heritage e-training portal    Sisi launches new support initiative for families of war, terrorism victims    Egypt expands e-ticketing to 110 heritage sites, adds self-service kiosks at Saqqara    Palm Hills Squash Open debuts with 48 international stars, $250,000 prize pool    On Sport to broadcast Pan Arab Golf Championship for Juniors and Ladies in Egypt    Golf Festival in Cairo to mark Arab Golf Federation's 50th anniversary    Germany among EU's priciest labour markets – official data    Paris Olympic gold '24 medals hit record value    A minute of silence for Egyptian sports    Russia says it's in sync with US, China, Pakistan on Taliban    It's a bit frustrating to draw at home: Real Madrid keeper after Villarreal game    Shoukry reviews with Guterres Egypt's efforts to achieve SDGs, promote human rights    Sudan says countries must cooperate on vaccines    Johnson & Johnson: Second shot boosts antibodies and protection against COVID-19    Egypt to tax bloggers, YouTubers    Egypt's FM asserts importance of stability in Libya, holding elections as scheduled    We mustn't lose touch: Muller after Bayern win in Bundesliga    Egypt records 36 new deaths from Covid-19, highest since mid June    Egypt sells $3 bln US-dollar dominated eurobonds    Gamal Hanafy's ceramic exhibition at Gezira Arts Centre is a must go    Italian Institute Director Davide Scalmani presents activities of the Cairo Institute for ITALIANA.IT platform    







Thank you for reporting!
This image will be automatically disabled when it gets reported by several people.



Pfizer in merger talks with Botox-maker Allergan: WSJ
Published in Amwal Al Ghad on 29 - 10 - 2015

Pharmaceutical giant Pfizer Inc (PFE.N) recently approached Botox-maker Allergan Plc (AGN.N) to discuss what could be the biggest takeover deal this year, the Wall Street Journal said on Wednesday, citing people familiar with the matter.
The healthcare sector has seen an unprecedented wave of deals since early 2014, from large drugmakers buying up smaller rivals, to consolidation among makers of generic medicines and tie-ups between insurers.
A bid for Allergan, which has a market value of $113 billion, would be Pfizer's second attempt to acquire a European rival, following its unsuccessfully courtship last year of Anglo-Swedish pharmaceuticals group AstraZeneca Plc (AZN.L).
After six months of negotiation, AstraZeneca rejected Pfizer's final bid in May 2014. The potential for lowering Pfizer's tax bill by switching its headquarters from the United States to the United Kingdom was touted by Chief Executive Officer Ian Read as a key reason for the deal.
A takeover of Allergan could offer similar advantages given that the Botox maker is based in lower-tax Dublin. A U.S. attempt to crack down on such tax avoidance deals led to the collapse of AbbVie Inc's (ABBV.N) bid to buy Shire Plc (SHP.L), but it is unclear whether those rule changes would preclude potential tax advantages from a Pfizer-Allergan deal.
"When you're the size of Pfizer, an acquisition like this may be the only choice you have in order to be able to move the needle for sequential growth...so the question now becomes, if not this, what, and if not now, when?" said WBB Securities' analyst Stephen Brozak.
Pfizer, which has a market value of about $219 billion, is the largest U.S. drugmaker.
Allergan would give Pfizer, whose revenues are expected to slide 3.3 percent this year, a boost in top-line growth. The Botox-maker's revenue is seen increasing 39 percent this year, according to Thomson Reuters I/B/E/S estimates.
The merger talks are in early stages, and may not yield an agreement, while other details are unclear, the Wall Street Journal said. (on.wsj.com/1XA0qdo)
Reuters was not immediately able to confirm the report.
Pfizer last month paid $15 billion to acquire U.S. rival Hospira Inc. The U.S.-based maker of such blockbuster drugs as Lipitor and Viagra was not immediately available for comment.
Allergan, which declined to comment, became the third-largest generic drugmaker in the United States after combining with Actavis in March.
Its chief executive, Brent Saunders, has been eager to do deals, having first orchestrated the sale of Forest Laboratories Inc, where he was initially CEO, to Actavis, then using the latter to seal the $66 billion purchase of Allergan.
Following the Actavis tie-up, Allergan sold its generic drugs business to Israel's Teva Pharmaceutical Industries (TEVA.TA) (TEVA.N) in July for $40.5 billion in cash and stock. And Saunders said after that he hoped to use those proceeds to do another large, "transformational" merger.
Both Pfizer and Allergan's shares were little changed after the bell on Wednesday. Shares of both companies have gained about 12 percent so far this year.
In its first full quarter after the Actavis deal, Allergan reported second-quarter revenue of $5.76 billion, led by $632 million in sales of wrinkle blocker Botox. Other top-selling drugs include dry eye treatment Restasis and Alzheimer's drug Namenda.
Pfizer recently reported third-quarter revenue of $12.1 billion, including $1.58 billion for its Prevnar pneumococcal vaccines and $947 million for pain drug Lyrica.
While Pfizer wanted to buy AstraZeneca in part to boost Pfizer's pipeline of cancer drugs, a deal with Allergan would involve dermatology drugs and generics.
Source: Reuters


Clic here to read the story from its source.